Chillon Jean-Marc, Baumbach Gary L
Cardiovascular Research Group, Faculté de Pharmacie de l'Université Henri Poincaré-Nancy I, Nancy, France.
J Hypertens. 2004 Mar;22(3):529-34. doi: 10.1097/00004872-200403000-00015.
Cerebral arterioles in stroke-prone spontaneously hypertensive rats (SHRSP), but not in Sprague-Dawley rats with hypertension induced by nitric oxide (NO) synthase inhibition, undergo inward remodeling. The goal of this study was to determine whether development of vascular inward remodeling may depend on genetic factors.
We examined effects of NO synthase inhibition on the structure of cerebral arterioles in Wistar-Kyoto rats (WKY), a rat strain genetically distinct from Sprague-Dawley.
Pressure (servonull), diameter (cranial window) and cross-sectional area of the vessel wall (CSA, histologically) were measured in maximally dilated (EDTA) cerebral arterioles in WKY, untreated (n = 8) or treated for 3 months with the NO synthase inhibitor N-nitro-L-arginine methyl ester (L-NAME) (10 mg/kg per day, n = 10) in the drinking water, and in untreated SHRSP (n = 7).
Treatment with L-NAME in WKY increased mean cerebral arteriolar pressure (69 +/- 7 versus 47 +/- 7 mmHg, P < 0.05) and pulse pressure (30 +/- 3 versus 17 +/- 1 mmHg, P < 0.05) to levels significantly lower than in SHRSP (98 +/- 5 and 35 +/- 1 mmHg respectively, P < 0.05). CSA was significantly greater in L-NAME-treated WKY and SHRSP than in untreated WKY (1692 +/- 50 and 1525 +/- 98 microm respectively, versus 1224 +/- 85, P < 0.05). External diameter was significantly less in L-NAME-treated WKY than in untreated WKY (119 +/- 5 versus 135 +/- 4 microm, P < 0.05) but significantly greater than in SHRSP (98 +/- 1 microm, P < 0.05).
Cerebral arterioles undergo hypertrophy and remodeling in WKY with L-NAME-induced hypertension. These findings suggest that genetic factors present in WKY and SHRSP may play a role in the development of vascular inward remodeling during chronic hypertension in rats.
易卒中型自发性高血压大鼠(SHRSP)的脑小动脉会发生内向重塑,而一氧化氮(NO)合酶抑制诱导高血压的Sprague-Dawley大鼠则不会。本研究的目的是确定血管内向重塑的发生是否可能取决于遗传因素。
我们研究了NO合酶抑制对Wistar-Kyoto大鼠(WKY)脑小动脉结构的影响,WKY是一种在遗传上与Sprague-Dawley不同的大鼠品系。
测量WKY未经治疗(n = 8)或饮用含NO合酶抑制剂N-硝基-L-精氨酸甲酯(L-NAME)(10 mg/kg/天,n = 10)3个月的最大扩张(乙二胺四乙酸)脑小动脉的压力(伺服零位)、直径(颅窗)和血管壁横截面积(CSA,组织学方法),以及未经治疗的SHRSP(n = 7)的上述指标。
WKY大鼠用L-NAME治疗后,平均脑小动脉压(69±7对47±7 mmHg,P<0.05)和脉压(30±3对17±1 mmHg,P<0.05)升高,但显著低于SHRSP(分别为98±5和35±1 mmHg,P<0.05)。L-NAME治疗的WKY和SHRSP的CSA显著大于未经治疗的WKY(分别为1692±50和1525±98μm²,对1224±85,P<0.05)。L-NAME治疗的WKY的外径显著小于未经治疗的WKY(119±5对135±4μm,P<0.05),但显著大于SHRSP(98±1μm,P<0.05)。
WKY大鼠在L-NAME诱导的高血压中脑小动脉会发生肥大和重塑。这些发现表明,WKY和SHRSP中存在的遗传因素可能在大鼠慢性高血压期间血管内向重塑的发生中起作用。